Evidence map›Paper›PMID 36420820›Full record

ArticleChemistry (Weinheim an der Bergstrasse, Germany)2023

Clearing an ESKAPE Pathogen in a Model Organism; A Polypyridyl Ruthenium(II) Complex Theranostic that Treats a Resistant Acinetobacter baumannii Infection in Galleria mellonella.

Kirsty Smitten, Hannah M Southam, Simon Fairbanks, Arthur Graf, Adrien Chauvet, Jim A Thomas

Open access · hybridAbstract read
In one paragraph

Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Phenazine Cations as Anticancer TheranosticsJournal of the American Chemical Society · 2024
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Kirsty SmittenDepartment of Chemistry, University of Sheffield, Sheffield, S3 7HF, UK.
Hannah M SouthamSchool of Bioscience, University of Sheffield, Sheffield, S10 2TN, UK.
Simon FairbanksDepartment of Chemistry, University of Sheffield, Sheffield, S3 7HF, UK.
Arthur GrafDepartment of Chemistry, University of Sheffield, Sheffield, S3 7HF, UK.
Adrien ChauvetDepartment of Chemistry, University of Sheffield, Sheffield, S3 7HF, UK.
Jim A ThomasDepartment of Chemistry, University of Sheffield, Sheffield, S3 7HF, UK.ORCID http://orcid.org/0000-0002-8662-7917
University of Sheffield · GB

Funding

Medical Research Council MK/K0157531/1
6 · The paper itself

Abstract

In previous studies we have described the therapeutic action of luminescent dinuclear ruthenium(II) complexes based on the tetrapyridylphenazine, tpphz, bridging ligand on pathogenic strains of Escherichia coli and Enterococcus faecalis. Herein, the antimicrobial activity of the complex against pernicious Gram-negative ESKAPE pathogenic strains of Acinetobacter baumannii (AB12, AB16, AB184 and AB210) and Pseudomonas aeruginosa (PA2017, PA_ 007_ IMP and PA_ 004_ CRCN) are reported. Estimated minimum inhibitory concentrations and minimum bactericidal concentrations for the complexes revealed the complex shows potent activity against all A. baumannii strains, in both glucose defined minimal media and standard nutrient rich Mueller-Hinton-II. Although the activity was lower in P. aureginosa, a moderately high potency was observed and retained in carbapenem-resistant strains. Optical microscopy showed that the compound is rapidly internalized by A. baumannii. As previous reports had revealed the complex exhibited no toxicity in Galleria Mellonella up to concentrations of 80 mg/kg, the ability to clear pathogenic infection within this model was explored. The pathogenic concentrations to the larvae for each bacterium were determined to be≥10

Indexed as

Acinetobacter baumanniiMothsRutheniumAnimalsAnti-Bacterial AgentsEscherichia coliMicrobial Sensitivity TestsPrecision MedicineAnti-Bacterial AgentsRutheniumAMRantimicrobialESKAPErutheniumtheranostic

Identifiers

PMID36420820
PMCPMC10946903
OpenAlexW4309928733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.